Member Contact: David Reddy
Position: Chief Executive Officer
Industry: Government and Not-for-Profit
"Medicines for Malaria Venture (MMV) is a highly successful, global, not-for-profit partnership between industry, government and the philanthropic sector to develop and deliver new medicines to treat and prevent malaria for vulnerable populations.
Based in Geneva, Switzerland, MMV has established strong partnerships with Australian scientists, for example at Monash University, the Walter and Eliza Hall Institute and Griffith University, along with Australian mining industry partners to develop new drugs to save lives in AsiaPacific and globally.
These partners contribute to MMV’s global drug development consortium of over 140 public and private partners in 47 countries across the world.
Over the past decade, MMV has developed the largest portfolio of drugs and drug candidates in history. Four drugs have been registered, one for children and one for severe malaria, now saving hundreds of thousands of lives particularly in Africa.
MMV’s strategy is to accelerate the response to emerging malaria drug resistance and to develop new drugs targeting women and children, particularly in AsiaPacific"